Testing a new cancer drug alongside standard prostate cancer treatment

This trial is testing a medication called saruparib alongside standard prostate cancer treatment in men who have a BRCA gene mutation. About 700 men will be randomly assigned to receive either saruparib or a placebo (a dummy pill) along with their regular hormone therapy and, in some cases, another standard drug. The goal is to see if adding this medication helps prevent the cancer from spreading to other parts of the body.

Men with BRCA mutations who have prostate cancer may have a higher risk of their cancer returning or spreading even after radiation and hormone therapy. Researchers believe this medication might work better for these patients because it targets a weakness related to their BRCA mutation, potentially preventing the cancer from advancing.